Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases.
- Author:
Bao-gui WANG
1
;
Han LIANG
;
Qing-hao CUI
;
Jia-cang WANG
;
Jian-zhong LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; therapeutic use; Chemotherapy, Adjuvant; Cyclophosphamide; administration & dosage; Doxorubicin; administration & dosage; Female; Follow-Up Studies; Histiocytoma, Benign Fibrous; secondary; surgery; therapy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Postoperative Period; Prednisone; administration & dosage; Prognosis; Radiotherapy, Adjuvant; Retroperitoneal Neoplasms; pathology; surgery; therapy; Retrospective Studies; Splenectomy; Survival Rate; Vincristine; administration & dosage
- From: Chinese Journal of Oncology 2004;26(6):373-374
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the diagnosis and treatment of malignant fibrous histiocytoma of the retroperitoneum (MFHR).
METHODSThe clinicopathological features, treatment and prognosis of 31 patients with MFHR were retrospectively analyzed.
RESULTSThe mean age of the patients was 52.7 +/- 14.1 years. Male:Female = 22:9. The primary symptoms were abdominal mass and pain. The average diameter of tumor was 15 cm. The histopathologic types of the tumor were inflammatory, storiform-pleomorphic, myxoid and giant cell in 16, 10, 4 and 1 cases. The overall survival rate of 1-, 3- and 5-year was 61.3% +/- 9.8%, 31.6% +/- 11.3% and 21.1% +/- 11.4% with a median survival time of 17.0 +/- 6.3 months. Complete resection of the tumor was the major prognostic factor. Postoperative radiotherapy of 20 - 45 Gy was able to prolong the median survival from 12.1 +/- 11.6 months of surgery alone to 26.4 +/- 22.0 months of surgery plus postoperative radiotherapy though without statistical significance (P = 0.051). Postoperative CHOP chemotherapy was not shown to be beneficial.
CONCLUSIONChemotherapy remains the important method of cure. The survival in patients with MFHR might be improved by complete resection combined with chemotherapy or/and radiotherapy.
